MedTrace Logo

Increasing the Effectiveness of the Diabetes Prevention Program

NCT02008435 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2018-03-21

No results posted yet for this study

Summary

The Diabetes Prevention Program (DPP) is highly effective in promoting weight loss in overweight and obese individuals (e.g., 7% average loss of body weight), and thereby reducing the risk of developing weight-related health consequences. One-on-one DPP sessions, however, are costly and the group-delivered DPP version, the Group Lifestyle Balance program (GLB), is less effective (4% average loss of body weight). The aim of this two-arm parallel randomized controlled trial is to increase the effectiveness of the GLB by integrating habit formation techniques, namely if-then plans and their mental practice, into the program. The study will provide evidence-based data on the effectiveness of an enhanced GLB intervention in promoting weight loss and in reducing weight-related risk factors for chronic health problems.

Conditions

Interventions

BEHAVIORAL

Enriched GLB

Habit formation techniques, namely if-then plans and their mental practice are being added to the standard Group Lifestyle Balance program.

BEHAVIORAL

Standard GLB

This arm is the standard Group Lifestyle Balance program

Sponsors & Collaborators

Principal Investigators

  • Barbel Knauper, PhD · McGill University

  • Ilka Lowensteyn, PhD · McGill University

  • Lawrence Joseph, PhD · McGill University

  • Aleksandra Luszczynska, PhD · University of Colorado, Denver

  • Steven Grover, MD · McGill University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02008435 on ClinicalTrials.gov